Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II) - Danese, Silvio; Vermeire, Séverine; Hellstern, Paul; Panaccione, Remo; Rogler, Gerhard; Fraser, Gerald; Kohn, Anna; Desreumaux, Pierre; Leong, Rupert W; Comer, Gail M; Cataldi, Fabio; Banerjee, Anindita; et al. (Gut, 2019)
Keywords: Apoptosis; Clinical medicine; Clinical trials; Crohn's disease; Cytokines; Employees; Gangrene; Gastroenterology; Immunoglobulins; Inflammation; Inflammatory Bowel Disease; Interleukin 6; Lupus; Pain; Patients; R&D; Remission; Research & development; Rheumatoid arthritis; Rhinopharyngitis; Studies; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; inadequate response; anti-IL6 antibody; crohn’s disease; anti-TNF